Pharmafile Logo

Alcon

- PMLiVE

Novartis presents positive results from two phase 3 trials for relapsing MS

Remibrutinib reduced relapse rates and improved disease progression rates

- PMLiVE

Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica

If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica

- PMLiVE

Novartis announces trial results for remibrutinib in relapsing multiple sclerosis

MS affects nearly three million people worldwide and has three main types

- PMLiVE

Sandoz announces collaboration agreement with Shanghai Henlius Biotech

The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company

- PMLiVE

Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer

More than 186,000 men are diagnosed each year with mHSPC globally

- PMLiVE

Cases of skin cancer set to reach 263,000 in 2035 according to new report

The report forecasts a rise in cases in the US, the UK, Canada, Australia and Europe

- PMLiVE

Novartis to acquire Myricx Bio in deal worth $1.5bn

Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates

- PMLiVE

Novartis breaks ground on US radioligand therapy site

The construction is part of the company’s investment in US research and manufacturing

- PMLiVE

Lilly commits additional $4.5bn for US manufacturing sites

The company has also opened its first dedicated genetic medicine facility in Indiana in the US

- PMLiVE

Potential US-Iran peace deal to redraw market winners and losers

With a 10-day ceasefire between Israel and Lebanon in effect, oil prices are retreating from recent highs

- PMLiVE

Novartis to acquire Excellergy in deal worth up to $2bn

Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases

- PMLiVE

Sandoz partners with Samsung Bioepis to develop up to five biosimilars

The agreement will expand the pipeline and builds on an existing partnership

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links